Home / Market News / $LH
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

UBS Adjusts Price Target on Labcorp to $420 From $380, Maintains Buy Rating

Oct 29, 2026, 6:09 PM UTC · Primary ticker $LH

UBS has increased its price target for Labcorp to $420 from $380, while reiterating a Buy rating. This adjustment follows the company's Q3 2026 earnings call, indicating a positive analyst sentiment post-results.

UBS has updated its outlook on Labcorp, raising its price target from $380 to $420 and maintaining a 'Buy' rating. This positive revision comes after Labcorp's third-quarter 2026 earnings call, suggesting that the analyst firm found the company's recent performance or outlook favorable. For traders, this indicates continued analyst confidence in Labcorp's future performance, potentially leading to positive short-term sentiment and upward pressure on the stock. The long-term implication is that UBS sees significant upside potential, reinforcing the investment thesis for existing shareholders and attracting new investors. A key opportunity for traders is to consider this analyst upgrade as a signal of underlying strength, though market reaction will depend on broader sentiment and the actual Q3 results that prompted this change.

$LH positive Price target increase and maintained Buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.